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sedimentation rate—ESR, white blood cell 
count) or evidence of pericardial inflamma-
tion detected by imaging technique, for ex-
ample cardiac magnetic resonance (CMR).[1]
Recurrent pericarditis is defined as a re-
lapse of disease after a documented first epi-
sode followed by a symptom-free interval of 
4-6 weeks or longer, arbitrarily defined by 
experts and corresponding to the completion 
and usual duration of anti-inflammatory 
therapy. Diagnosis of recurrence is estab-
lished according to the same criteria as those 
used for acute pericarditis.[1]
The recurrence rate after an initial epi-
sode of pericarditis ranges from 15 to 30% 
and may increase to 50% after a first recur-
rence in patients not adequately treated.[1] 
(ClinicalTrials.gov registration number: 
NCT00128414 [2]; ClinicalTrials.gov reg-
istration number: NCT00235079 [3]).
IntroduCtIon
Acute pericarditis is an inflammatory peri-
cardial syndrome, defined when at least two 
of the four following criteria are satisfied:
 y Chest pain, typically retrosternal, wors-
ened in supine position and with deep in-
spiration, relieved in the upright position;
 y Pericardial friction rub (unfortunately 
this sign is present only in one third of 
all patients);
 y Typical electrocardiographic features, 
namely PR depression and diffuse concave 
ST segment elevation;
 y New onset or worsening pericardial ef-
fusion.
Other supportive findings for diagnosis 
are fever, elevation of markers of inflamma-
tion (C-reactive protein—CRP, erythrocyte 
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Abstract
Recurrent pericarditis is defined when pericarditic chest pain reappears after a symptom-free 
period of at least 4 to 6 weeks and after completion of full-dose anti-inflammatory therapy. 
Idiopathic pericarditis is the commonest etiology. The diagnosis of idiopathic cases is essentially 
an exclusion diagnosis, supported by a typical clinical course. The diagnosis is based on the 
association of typical symptoms and signs: mainly pericarditic chest pain plus pericardial rubs 
or electrocardiographic alterations or pericardial effusion. The optimal regimen for recurrences 
includes combination of non-steroidal anti-inflammatory agents, colchicine, and corticosteroids. 
In the resistant forms, immunotherapy (azathioprine, intravenous immunoglobulins, and 
particularly anakinra) has shown to be effective. The long term outcome of idiopathic recurrent 
pericarditis is good, with no evolution towards constrictive form.
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Patients at risk for recurrent attacks 
are patients with incomplete response to 
non-steroidal anti-inflammatory drugs 
(NSAIDs), patients with high fever or large 
effusion at presentation or elevated C re-
active protein despite at least one week of 
treatment.[1] Other treatment-related risk 
factors are: inadequate initial full dose of 
NSAIDs regimen or too rapid drug tapering, 
corticosteroids use, lack of colchicine, dis-
continuation of two classes of drugs together.
Other known mechanisms classically in-
volved include exacerbations of the initial 
infections or reinfections and unrecognized 
cause untreated. Some factors that may trig-
ger the recurrence are acute respiratory in-
fections, physical efforts, cold temperature 
exposition.[4]
ClInICAl MAnAgeMent
The main symptom of recurrent pericardi-
tis is chest pain, similar in characteristics to 
the pain suffered in the first episode, but in 
most cases less powerful, more attenuated. 
The chest pain of pericarditis is typically 
retrosternal in location, sudden in onset, 
pleuritic in nature. Chest pain is worse when 
the patient is supine and improves when he 
or she sits upright. Chest pain is exacerbated 
by inspiration. A prodromal of fever, malaise, 
and myalgia can be common.[5]
Auscultation, electrocardiograph (ECG), 
echocardiography, chest X-ray, and routine 
blood tests are first-level investigations, rec-
ommended in all cases (Table I).[1]
During physical examination some pa-
tients have an audible friction rub.
ECG can show upward concave ST-seg-
ment elevation and PR-segment depression. 
In recurrent pericarditis, nonspecific altera-
tions of ventricular repolarization or abnor-
malities of T-waves are common.
Transthoracic echocardiography can re-
veal the presence of a new onset or worsened 
pericardial effusion.
Chest X-ray provides information with 
regard to cardiac size and the presence of 
pulmonary pathology, pleural effusion and 
hilar and mediastinal enlargement.
Blood tests to perform are white cell 
count, ESR and CRP, renal function and 
liver tests, thyroid function, markers of myo-
cardial injury.[1] Unfortunately, no specific 
diagnostic marker is available for pericardi-
tis. However, most patients with pericarditis 
show high levels of markers of inflammation. 
level Investigation
First level (all cases)  y Markers of inflammation (CRP, ESR, white blood cell count)
 y Renal function and liver tests, thyroid function
 y Markers of myocardial lesion (troponin)
 y ECG
 y Echocardiography
 y Chest X-ray
Additional testing 
directed to 
specific etiologies 
according to clinical 
presentation
Probable viral 
infections
 y Viral serological tests are not recommended, with the 
possible exception of anti-HIV, anti-HCV, HBsAg
Probable 
tuberculosis
 y Quantiferon, Mantoux
 y Culture and PCR in sputum or other biological fluids
 y Chest CT Scan
 y Acid-fast bacilli staining, Mycobacterium cultures, PCR for 
genome on pericardial fluid
Probable 
neoplasm
 y Specific neoplasm markers
 y Chest and abdomen CT scan, PET
 y Cytology of pericardial fluid or pericardial biopsy
Probable 
autoimmune 
disease
 y ANA, ENA, ANCA, ACE, RF, ferritin
Probable 
autoinflammatory 
conditions 
(periodic fevers)
 y FMF and TRAPS mutations
Second level (first level not sufficient for 
diagnostic purpose)
 y Computed tomography and/or cardiac magnetic resonance
 y Pericardiocentesis (analysis of pericardial fluid)
table I. Recommended 
investigations for 
pericarditis.[1]
ACE = angiotensin-
converting enzyme; 
ANA = antinuclear 
antibodies; ANCA = anti-
neutrophil cytoplasm 
antibodies; CRP = C-reactive 
protein; ENA = anti-
extractable nuclear antigens; 
ESR = erythrocyte 
sedimentation rate; 
FMF = familial 
Mediterranean fever; 
RF = rheumatoid factor; 
TRAPS = tumor necrosis 
factor receptor associated 
periodic syndrome
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CRP and ESR and the other parameters of 
inflammation, even though not specific, are 
very important to define the intensity of the 
inflammatory process and select appropriate 
length of therapy. For example, CRP dos-
age can be useful to confirm the diagnosis 
and differentiate true relapses from atypical 
chest pains. Persistent elevation of CRP may 
indicate ongoing inflammation and requires 
prolonged therapies. Monitoring of CRP 
may be useful to follow the disease activity 
and to guide the appropriate length of ther-
apy, with continuation of the full dose until 
CRP normalization, at which time tapering 
may be considered. During the therapy, in 
addition to the monitoring of side effects, 
a monthly check of CRP, blood cell count, 
renal and hepatic function, inflammatory 
index is strongly recommended.[6]
The diagnostic work-up of recurrent peri-
carditis may provide the use of second-level 
investigations in order to identify specific 
etiologies or detect if significant pericardial 
inflammation persists despite therapy. The 
identification of an underlying etiology is 
particularly important because it allows to 
start a targeted therapy.[1,7,8]
Many diseases can cause pericarditis, but, 
for a practical approach, causes can be divid-
ed in two major categories: infectious (any 
kind of microorganisms) and non-infectious 
causes (autoimmune, neoplastic, metabolic, 
traumatic or iatrogenic, drug-related, and 
miscellaneous).[1]
In developed countries and in immuno-
competent patients, recurrent pericarditis is 
idiopathic or viral in most cases (80-85%). 
Viral infections causing pericarditis include 
coxsackievirus, echovirus, adenovirus, par-
vovirus, human herpes virus 6, but specific 
viral serological tests are considered futile. 
The diagnosis of idiopathic cases is essen-
tially an exclusion diagnosis, supported by 
a typical clinical course.[1,7,8]
In patients with repeated relapses and in 
presence of certain clinical features, it is im-
portant to exclude some etiologies that may 
not have been identified in previous assess-
ments: tuberculosis, systemic inflammatory 
diseases, such as a connective tissue disease 
or neoplastic diseases.[1]
In this regard, specific blood tests, com-
puted tomography (CT), positron emission 
tomography (PET), and cardiac magnetic 
resonance (CMR) may be useful.
CT is considered a complementary im-
aging modality. CT generally provides ana-
tomic information and defines the extent of 
pericardial calcification, but with adminis-
tration of iodinated contrast medium it is 
possible to detect pericardial inflammation 
because of the enhancement of the inflamed 
pericardium after contrast injection.[9] CT, 
if extended to thorax and abdomen, may 
detect neoplastic masses or lymphadenopa-
thies, thus suggesting possible tuberculosis.
In selected cases, PET, preferably in com-
bination with CT, can be indicated to depict 
the metabolic activity of pericardial disease. 
Pericardial uptake of tracer in patients with 
solid cancers and lymphoma is indicative 
of malignant pericardial involvement, thus 
providing key information on the diagnosis, 
staging, and assessment of the therapeutic 
response. PET/CT is also of value in iden-
tifying the nature of inflammatory pericar-
ditis. For example, tuberculosis pericarditis 
yields higher tracer uptakes than the idio-
pathic forms.[10]
Cardiac magnetic resonance is a very help-
ful second-level imaging technique to study 
pericardial tissue. CMR assesses pericardial 
thickness and can have a significant role in 
the evaluation of pericardial inflammation. 
Following intravenous administration of 
gadolinium, late gadolinium enhancement 
can show the extension of the inflammation 
into the surrounding epicardial fat, suggest-
ing a severe inflammation. Some patient, es-
pecially those with complicated or recurrent 
pericarditis, may benefit from this exam pri-
marily directed at identifying if the patient 
still has significant pericardial inflamma-
tion. CMR is indicated also in patients in 
whom the presence of active pericardial in-
flammation is uncertain: delayed pericardial 
enhancement at CMR may favor continued 
or intensified anti-inflammatory treatment. 
On the other hand, if CMR does not show 
delayed pericardial enhancement, then ta-
pering of medications may continue, and 
other diagnosis may be considered. CMR 
is useful also to show myocardial inflam-
matory involvement, fibrosis, and constric-
tive evolution. Unfortunately, the technique 
has some important disadvantages: limited 
availability, high costs, and also the need for 
breath-holding and regular heart rhythms to 
get a better quality of the picture.[4]
As stated in the most updated European 
Society of Cardiology (ESC) guidelines,[1] 
pericardiocentesis should be used just in 
case of cardiac tamponade and suspicion of 
neoplastic or bacterial etiology as absolute 
indications. Moreover, it should be consid-
ered in case of chronic (> 3 months) large 
pericardial effusions.
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ter indomethacin 100 mg in 250 ml of saline 
in continuous infusion in a day. Therefore, 
after 3-5 days of intravenous indometha-
cin, if the patient is better, i.v. indomethacin 
can be switched to oral therapy. Ketorolac 
is another anti-inflammatory widely used 
intravenously in the hospital setting, but it 
can only be used for a short time and, on the 
contrary, patients with relapsing pericarditis 
need the therapy for a long time.
Particular attention should be paid in us-
ing the highest tolerable dose of each medi-
cation and reassuring a continuous anti-
inflammatory coverage throughout the day. 
A common mistake is to use too low doses. 
Aspirin should be used at the dose of 1.5 
to 4 g/day; ibuprofen 1800-2400 mg/day; 
indomethacin 75-150 mg/day (Table II).
The administration of NSAIDs should be 
well distributed during the day. For example, 
with regard to aspirin, ibuprofen, or indo-
methacin, each dose should be taken pre-
cisely every 8 hours in order to guarantee a 
full 24-hour coverage.[8,11]
The duration of optimal treatment and 
the need to reduce the dose have not been 
tested in clinical trials. It is well established 
that the full dose regimen should be offered 
at least until normalization of CRP values 
and initial clinical remission. This may take 
months, especially in patients with history of 
recurrent pericarditis. Generally, respect the 
first episode of acute pericarditis, the length 
of treatment should be more extended.
NSAIDs’ side effects are well known. The 
most serious are ulcers, bleeding, and kid-
ney failure.
Aspirin use should be more cautious in 
patients with initial impaired renal function, 
drug Attack dose length of treatment* tapering
Aspirin 500-1500 mg every 8 hours 
(1.5-4 g/d)
First attack: 2-4 weeks
Recurrences: several 
weeks/months.
The optimal length 
of treatment is 
debatable, and CRP 
should probably be as 
a marker of disease 
activity to guide 
management and length 
of treatment. Gradual 
tapering (every 1-2 
weeks and only if the 
patient is asymptomatic 
and CRP is normal) is 
recommended
Decrease the total daily 
dose by 250-500 mg 
every 2-4 weeks
Ibuprofen 600-800 mg every 8 hours 
(1800-2400 mg daily)
Decrease the total daily 
dose by 200-400 mg 
every 2-4 weeks
Indomethacin 25-50 mg every 8 hours
(75-150 mg daily)
Decrease the total daily 
dose by 25 mg every 
2-4 weeks
Naproxen 250-500 mg every 12 hours; maximal 
daily dose 1500 mg for limited 
time period (< 6 months). Dosage 
expressed as naproxen base; 200 mg 
naproxen base is equivalent to 
220 mg naproxen sodium
Decrease the total daily 
dose by 125-250 mg 
every 1-2 week
table II. Commonly 
prescribed 
anti‑inflammatory 
therapies and dosages for 
recurrent pericarditis.[1]
*Valid for all alternatives
therApy
The treatment of patients with recurrences 
is not very different to the treatment of a 
first episode of acute pericarditis. Aspirin 
or NSAIDs remain the mainstay of ther-
apy. Colchicine is recommended on top of 
standard anti-inflammatory therapy in or-
der to improve remission rates and prevent 
recurrences. In case of incomplete response 
to NSAIDs and colchicine, corticosteroids 
may be used, but they should be added at 
low-to-moderate doses.[1]
Aspirin and nSAIds
Aspirin and NSAIDs remain the main-
stay of treatment.[1,7,8] The specific drug 
selected is not important: the choice should 
be based on the physician’s experience as well 
as on the history of efficacy and tolerability 
in the single patient. An NSAID that was 
effective in a previous attack should be the 
favorite choice. Ibuprofen and aspirin are 
the most used. Indomethacin is perhaps the 
most powerful anti-inflammatory drug. Also 
comorbidities are important: for example, 
aspirin is the favored choice in patients with 
ischemic heart disease or when a patient 
is already on aspirin or needs anti-platelet 
treatment. Also naproxen is an alternative 
in these situations. Indomethacin and other 
NSAIDs should be avoided in patients with 
coronary artery disease.
During an acute attack, a practical tip in a 
hospitalized patient is the administration of 
aspirin or NSAIDs intravenously, above all 
if the patient has intensive pain, high fever 
with associated nausea or vomiting. For ex-
ample, in our clinical experience we adminis-
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that cases of recurrence after colchicine dis-
continuation have been reported. Even for 
colchicine, suspension should not be abrupt, 
but gradual.[2,3,12]
Corticosteroids
Corticosteroids are not recommended as 
first-line approach. It was shown that when 
they were used as first and unique therapy, 
though they produced a fast and satisfac-
tory clinical response, they created a kind 
of addiction, a chronicity, and the patient 
became dependent.
Corticosteroids should be considered only 
in specific situations and the indications for 
their use are limited, for example in case of 
incomplete response to aspirin/NSAIDs and 
colchicine. In this case, they should be added 
at low-moderate doses as triple therapy in 
order to achieve better control of symptoms. 
NSAIDs are really contraindicated in case 
of true allergy or intolerance, renal failure 
and advanced kidney disease, pregnancy 
beyond the 20th week of gestation, recent 
peptic ulcer or gastrointestinal bleeding, 
oral anticoagulant therapy when the bleed-
ing risk is considered high or unacceptable. 
Corticosteroids are also correctly used when 
there is an autoimmune disease. Indeed, low 
doses of steroids are commonly used to treat 
serositis.[1] Even in these cases, colchicine 
should be associated.
Although guidelines and reviews sug-
gest limiting the use of these drugs, they 
are commonly prescribed, especially during 
recurrences.
Low-to-moderate doses (0.2-0.5 mg/kg/
day of prednisone or dose equivalent, in most 
patients generally 5-10 mg/day) are suffi-
cient in most patients and the dose should 
almost never exceed 25 mg/day.[13]
Side effects are numerous and well known: 
weight gain, hypertension, diabetes, immu-
nosuppression with masked or latent oppor-
tunistic infections, osteoporosis, acute myop-
athy, elevated intraocular pressure, cataract, 
central nervous system effects ranging from 
euphoria to psychosis. In order to prevent 
osteoporosis, supplementation of calcium 
and vitamin D and bisphosphonates, when 
indicated, is performed. With the aim of 
preventing weight increase, hyperglycemia, 
and liquid retention, some rules must be 
respected, and in particular diet restriction 
is necessary.
After having obtained a clinical response, 
corticosteroids tapering should be very 
erosive gastritis, peptic ulcer, gout, platelet, 
and bleeding disorders. NSAIDs use should 
be more cautious in patients with cardiac 
dysfunction, hypertension, renal or hepatic 
impairment, epilepsy, and patients receiving 
anticoagulants. However, in most patients 
these medications are taken for months 
without causing significant side effects. A 
proton pump inhibitor should be prescribed 
to all patients under aspirin or NSAIDs 
treatment.[8,11]
Colchicine
In case of pericarditis, colchicine is al-
ways indicated, even in the first attack, but 
especially in case of recurrence. Colchicine 
should be added to the NSAIDs, and should 
not replace them.[1]
Colchicine therapy is able to improve the 
response to traditional anti-inflammatory 
therapy and reduce the relapse rate of at 
least 50%.[2,3]
Side effects are gastrointestinal (up to 
10% of cases), including nausea, vomiting, 
diarrhea, and abdominal pain, usually be-
ing a common cause of drug withdrawal; 
generally mild, they may resolve with dose 
reduction. Weight-adjusted doses may re-
duce these side effects. Less common side 
effects include elevation of transaminases. 
Other anecdotal side effects are bone mar-
row suppression (less than 1%) and reversible 
alopecia (0.6%). Colchicine interacts with 
macrolide antibiotics, in particular clarithro-
mycin. A practical advice is to halve the dose 
of colchicine while taking clarithromycin.
During the therapy with colchicine, it is 
recommended to monitor blood cell count, 
renal function, and transaminases at least at 
baseline and after a month of therapy. These 
exams are routinely performed in patients 
with many recurrences.
In order to improve patients’ compli-
ance and minimize the risk of side effects, 
colchicine should be administered in low, 
weight-adjusted doses (0.5 mg once daily 
for patients < 70 kg, 1 mg once daily or 
0.5 mg twice daily for patients > 70 kg). A 
loading dose is not necessary. Dose adjust-
ment is mandatory for patients with renal 
impairment, debilitated patients, and elderly 
patients.[1-3]
The duration of therapy is at least 6 
months, but, if recurrences are frequent and 
colchicine is well tolerated, the duration can 
reach some years. At this point, discontinua-
tion is discussed with the patient, explaining 
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steroids, and colchicine, the most updated 
ESC guidelines [1] suggest to consider the 
use of azathioprine, high-dose intravenous 
immunoglobulins, and anakinra.
Azathioprine is indicated for patients who 
require unacceptably high long-term doses 
of corticosteroids.[1] In these conditions, 
azathioprine is used as a steroid-sparing 
agent in order to control the disease at long-
term follow up. On the contrary, it is not 
useful in the resolution of an acute attack. 
Azathioprine is a purine analog that inhibits 
lymphocytes proliferation. It is commonly 
used in autoimmune diseases. Data concern-
ing azathioprine as therapy of recurrent peri-
carditis are scarce and based solely on adults’ 
case reports.[16] The treatment dose for 
recurrent pericarditis is 2 mg/kg daily. The 
major side effect is myelosuppression, which 
resolves by reducing the dose in about one 
week. Other side effects are transient hepa-
totoxicity and gastrointestinal symptoms.
Intravenous immunoglobulins (IVIGs) 
are used for their immunomodulatory and 
immunosuppressive effects.[1] IVIGs have a 
role in the resolution of acute attacks and as 
steroid-sparing agent. The most commonly 
used dose ranges from 400 to 500 mg/kg 
per day for 5 days. Repeated cycles may be 
required, typically at monthly intervals. The 
main disadvantages of this treatment are 
costs and possible safety problems related 
to the use of plasma-derived substances. 
Fortunately, adverse reactions are very rare, 
mild, and transient. Care must be taken in 
the infusion rate.
Anakinra is a recombinant form of in-
terleukin-1 (IL1) receptor antagonist and 
acts by antagonizing the biological effects 
of IL1, which is a pro-inflammatory cyto-
kine. A recent study, AIRTRIP, has shown 
that anakinra has a spectacular effect in 
severe, cortico-dependent and colchicine-
resistant idiopathic recurrent pericarditis 
(ClinicalTrials.gov registration number: 
NCT02219828 [16]). It is important to 
select the right patients, that are those with 
very active and inflammatory disease, fever, 
strikingly elevated CRP, pleural effusions. 
Anakinra is not indicated in patients with 
ambiguous recurrences with normal CRP. 
The initial dose is 100 mg/day; it is admin-
istered subcutaneously. The most common 
adverse effect is a local reaction at the injec-
tion site. For this reason, patients should be 
informed in advance. Local skin reactions 
disappear over one months or after topical 
steroids treatment and systemic antihista-
gradual, over months as in rheumatic poly-
mialgia. Table III shows a schedule about 
steroid reduction based on the dose used.[1]
A critical threshold is a 10-15 mg/day 
dose of prednisone or equivalent. At this 
threshold, decrements should be very slow, 
for example 1-2.5 mg at intervals of 2-6 
weeks. Each tapering should be performed 
only with normal CRP and in the absence 
of symptoms. In case of recurrence during 
tapering, an important advice is not to in-
crease the dose of steroid yet, but eventu-
ally split in 2 half doses controlling the 
symptoms, adding NSAIDs every 8 hours 
full dosage or intravenously, adding analge-
sics and reassuring the patient about dura-
tion of clinical disorders, generally only few 
days.[1]
triple therapy: a wand
A protocol including non-steroidal anti-
inflammatory drugs at high dosage, colchi-
cine, corticosteroids at low doses, reassur-
ance, and close clinical monitoring generally 
allow patients to obtain a good control of 
the disease.[1,14]
After obtaining a complete response, ta-
pering should be done with a single class of 
drugs at a time. We suggest this order of dis-
continuation: steroids first, NSAIDs second, 
and at last colchicine. Such process should 
be strictly individualized according to indi-
vidual intolerability and renal function, as in 
elderly people. Since steroid discontinuation 
may require from 2 to 10 months, during 
this time, according the clinical condition, 
NSAIDs can be used at low or intermedi-
ate doses and only temporarily increased at 
high doses. Since colchicine is generally well 
tolerated, it is the last drug to be stopped. In 
the acute attack, analgesics, like acetamino-
phen or tramadol, can be added to control 
the pain.[1]
Immunotherapy
In patients with recurrent pericarditis 
despite the therapy with NSAIDs, cortico-
Starting dose: 0.2-0.5 mg/kg/day tapering
> 50 mg 10 mg/day every 1-2 weeks
25-50 mg 5-10 mg/day every 1-2 weeks
15-25 mg 2.5 mg/day every 2-4 weeks
< 15 mg 1.25-2.5 mg/day every 2-6 weeks
table III. Tapering of 
corticosteroids (dosage 
information for 
prednisone).[1]
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a first (and thus non-recurrent) episode of 
pericarditis.
Therefore, despite compromising the qual-
ity of life, idiopathic recurrent pericarditis 
has an overall good long-term prognosis 
without significant risk of constrictive peri-
carditis, heart disease evolution, or death 
[17,18]. Cardiac tamponade is rare and gen-
erally occurs at the beginning of the disease.
In conclusion, if patients with recurrent 
pericarditis are treated with a multi-drug 
protocol in which NSAIDs are used at rec-
ommended dosages, colchicine is added if 
tolerated, steroids are tapered very slowly 
with a close clinical monitoring, the clini-
cal course and quality of life will show im-
provement. For those patients who do not 
respond to this protocol, anakinra can be a 
drug with spectacular results. An important 
component of therapy is reassurance and 
explanation of the nature of the disease and 
its likely course.
Key points in the management of recurrent pericarditis
 y Recurrent pericarditis generally has good prognosis, implies a nor‑
mal life, and presents no risk of evolution in constrictive pericarditis
 y Aspirin and NSAIDs are the mainstay of treatment and are recom‑
mended at full doses, well distributed, intravenously if necessary, 
until complete symptoms resolution
 y Colchicine at low dose (0.5‑1 mg/day) is recommended as an ad‑
junct to aspirin/NSAIDs. Colchicine therapy for long duration 
should be considered in some cases
 y Corticosteroid therapy is not recommended as first‑line approach. 
Low‑dose corticosteroids should be considered in case of contraindi‑
cation to aspirin/NSAID/colchicine or in case of incomplete response 
to aspirin/NSAID/colchicine
 y CRP dosage should be considered to guide the treatment duration 
and assess the response to therapy
 y After CRP normalization and symptoms resolution, a gradual 
tapering of therapies should be considered, in this order: first corti‑
costeroids, second NSAIDs or aspirin, third colchicine
 y Drugs such anakinra, azathioprine, or IVIG may be considered in 
case of corticosteroid‑dependent and colchicine‑resistant recurrent 
pericarditis
mines. Warming the syringe to room tem-
perature before use is advisable, along with 
application of a cold pack to the injection 
site approximately 2 to 3 minutes before and 
immediately after the injection to prevent 
local reactions. Other adverse effects are 
mild reversible elevation of transaminases 
and increased risk of infection. Neutropenia 
has been reported in 5% of cases, but without 
evidence of association with clinical events. 
The contraindications of its employment are 
acute infections, immunosuppression and 
neutropenia, hypersensitivity or a previous 
allergic reaction, pregnancy, and breastfeed-
ing. The main advantages of anakinra are 
rapid onset of effect (few days) and the ca-
pability to allow quick withdrawal of corti-
costeroids and then NSAIDs (some weeks).
In our experience, the duration of therapy 
is at least three months at full dose. After ob-
taining remission with anakinra, a very grad-
ual tapering is suggested (for example -100 
mg/week every month till 300 mg/weekly, 
and then -100 mg/week every 2-3 months), 
with concomitant colchicine therapy, avoid-
ing corticosteroids. This indication is due to 
the fact that unfortunately recurrences are 
common also after anakinra discontinuation.
pericardiectomy
If all drugs fail, the last option is the sur-
gical removal of the pericardium in experi-
enced surgical centers. The role of interven-
tional and surgical techniques for the treat-
ment of pericarditis is controversial, with the 
only exception of constrictive pericarditis. 
Fortunately, nowadays pericardiectomy is 
rarely required and should be regarded as 
the last resort in refractory pericarditis cas-
es presenting with recurrent tamponade, and 
in patients unable to tolerate the aforemen-
tioned conventional treatment.[1] Table IV 
shows the therapeutic algorithm for recur-
rent pericarditis.
ConCluSIon
Recurrent pericarditis is often a frus-
trating disease, for both the patient and 
the physician. Indeed, recurrences are a 
common cause of concern for the fear of a 
possible evolution towards constriction or 
heart disease. In this regard, an analysis of 
cases of idiopathic recurrent pericarditis has 
shown no cases of constrictive pericarditis 
even after a long-term follow up [17]. A low 
risk (0.4%) of constriction exists just after 
line therapy
First line Aspirin or NSAID + colchicine
Second line Low-dose corticosteroids (in case of contraindication to 
aspirin/NSAID/colchicines or in case of incomplete response 
to aspirin/NSAID/colchicine)
Third line Anakinra or azathioprine or IVIG
Fourth line Pericardiectomy
table IV. Therapeutic 
algorithm for recurrent 
pericarditis.[1]
IVIG = intravenous 
immunoglobulins
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The commonest misunderstandings
 y Low doses of NSAIDs, only orally or not well distributed to cover the day
 y High dose of colchicine: Diarrhea and discontinuation
 y Colchicine in monotherapy during the acute attack: It should be always added to an anti‑
inflammatory drug
 y Corticosteroids in monotherapy: Side effects and recurrences at discontinuation
 y Rapid tapering of steroids: Tapering should be very gradual, over months, only done af‑
ter symptoms resolution with normalization of CRP. If symptoms recur during therapy 
tapering, the management should consider not to increase the dose of corticosteroids, but 
control the symptoms increasing to the maximum the dose of aspirin or NSAIDs and 
adding analgesics.
 y Automatic tapering not depending on CRP normalization.
reFerenCeS
1. Adler Y, Charron P, Imazio M, et al. The task force for the diagnosis and management of 
pericardial diseases of the European society of cardiology (ESC) 2015 ESC Guidelines for 
the diagnosis and management of pericardial diseases. Eur Heart J 2015; 36: 2921-64; https://
doi.org/10.1093/eurheartj/ehv318
2. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP) a 
randomized trial. Ann Intern Med 2011; 155: 409-14; https://doi.org/10.7326/0003-4819-
155-7-201110040-00359
3. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple 
recurrences of pericarditis (CORP-2): a multicenter, double-blind, placebo-controlled, 
randomized trial. Lancet 2014; 383: 2232-7; https://doi.org/10.1016/S0140-6736(13)62709-9
4. Cremer PC, Kumar A, Kontzias A, et al. Complicated Pericarditis: understanding risk factors 
and pathophysiology to inform imaging and treatment. J Am Coll Cardiol 2016; 68: 2311-28; 
https://doi.org/10.1016/j.jacc.2016.07.785
5. Imazio M, Gribaudo E, Gaita F. Recurrent pericarditis. Prog Cardiovasc Dis 2017; 59: 360-8; 
https://doi.org/10.1016/j.pcad.2016.10.001
6. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and 
time course of normalization in acute pericarditis: implications for the diagnosis, therapy, 
and prognosis of pericarditis. Circulation 2011; 123: 1092-7; https://doi.org/10.1161/
CIRCULATIONAHA.110.986372
7. Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart 2015; 101: 1159-68; https://
doi.org/10.1136/heartjnl-2014-306362
8. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management 
of pericardial diseases. Circulation 2010; 121: 916-28; https://doi.org/10.1161/
CIRCULATIONAHA.108.844753
9. Maggiolini S, De Carlini CC, Ferri LA, et al. The role of early contrast-enhanced chest computer 
tomography in the etiological diagnosis of patients presenting with cardiac tamponade or large 
pericardial effusion. Euro Heart J Cardiovasc Imaging 2016; 17: 421-8; https://doi.org/10.1093/
ehjci/jev225
10. Lobert P, Brown RK, Dvorak RA, et al. Spectrum of physiological and pathological cardiac 
and pericardial uptake of FDG in oncology PET/CT. Clin Radiol 2013; 68: 59-71; https://
doi.org/10.1016/j.crad.2012.09.007
9© 2018 The Authors. Published by SEEd srl. This is an open access article under  
the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
Clinical  Management  Issues   2018; 12(1)
A. Assolari, S. Maestroni, D. Cumetti, A. Valenti, F. Parisi, A. Brucato 
11. Imazio M, Brucato A, Trinchero R, et al. Individualized therapy for pericarditis. Expert Rev 
Cardiovasc Ther 2009; 7: 965-75; https://doi.org/10.1586/erc.09.82
12. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicines for acute pericarditis. 
N Engl J Med 2013; 369: 1522-8; https://doi.org/10.1056/NEJMoa1208536
13. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis. High versus low 
doses: a nonrandomized observation. Circulation 2008; 118: 667-71; https://doi.org/10.1161/
CIRCULATIONAHA.107.761064
14. Brucato A, Brambilla G, Adler Y, et al. Therapy for recurrent acute pericarditis: a rheumatological 
solution? Clin Exp Rheumatol 2006; 24: 245-50
15. Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis; a single 
centre experience. Int J Cardiol 2011; 147: 477-8; https://doi.org/10.1016/j.ijcard.2011.01.027
16. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among 
patients with colchicines resistance and corticosteroid dependence: the AIRTRIP randomized 
clinical trial. JAMA 2016; 316: 1906-12; https://doi.org/10.1001/jama.2016.15826
17. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. 
Circulation 2011; 124: 1270-5; https://doi.org/10.1161/CIRCULATIONAHA.111.018580
18. Imazio M, Brucato A, Adler Y, et al. Prognosis of idiopathic recurrent pericarditis as determined 
from previously published reports. Am J Cardiol 2007; 100: 1026-8; https://doi.org/10.1016/j.
amjcard.2007.04.047
